Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Index
-
Market Cap
39.25M
Enterprise Value
31.59M
Income
-14.66M
Sales
0.00M
Book/sh
0.21
Cash/sh
0.27
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
12
IPO
Feb 11, 2011
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
3.66
P/C
2.77
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
3.19
Current Ratio
3.19
Debt/Eq
0.61
LT Debt/Eq
0.61
Option/Short
Yes / Yes
EPS (ttm)
-0.20
EPS next Y
-0.21
EPS next Q
-0.06
EPS this Y
42.65%
EPS next Y
-6.41%
EPS next 5Y
28.68%
EPS past 3/5Y
- 48.69%
Sales past 3/5Y
- -65.11%
EPS Y/Y TTM
46.24%
Sales Y/Y TTM
-100.00%
EPS Q/Q
50.28%
Sales Q/Q
-100.00%
Insider Own
25.69%
Insider Trans
0.00%
Inst Own
42.93%
Inst Trans
0.07%
ROA
-53.97%
ROE
-98.08%
ROIC
-85.17%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-24.24%
SMA50
-29.88%
SMA200
-25.33%
Trades
Shs Outstand
51.95M
Shs Float
38.61M
52W High
1.57 -51.89%
52W Low
0.69 10.01%
Volatility
14.34% 7.46%
ATR (14)
0.07
RSI (14)
20.44
Beta
0.80
Rel Volume
0.69
Avg Volume
147.70K
Volume
51,881
Perf Week
-27.02%
Perf Month
-29.41%
Perf Quarter
-36.53%
Perf Half Y
-7.63%
Perf YTD
-33.75%
Perf Year
-42.78%
Perf 3Y
52.65%
Perf 5Y
-94.75%
Perf 10Y
-98.80%
Prev Close
0.80
Price
0.76
Change %
-5.59%
Consensus
Strong Buy
Avg. Price Target
$3.12
Implied Upside
+313.1%
Analysts9incl. previous ratings
Rating Distribution5 Buy · 3 Hold · 1 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jun 05, 2026Resumed
HH.C. Wainwright
Buy$3+297.2%
Jan 28, 2025Initiated
RRodman & Renshaw
Buy$4+429.6%
Jul 20, 2020Downgrade
CCredit Suisse
Neutral → Underperform
Nov 11, 2019Downgrade
CCredit Suisse
Outperform → Neutral$7 → $2+164.8%
Aug 05, 2019Resumed
CCredit Suisse
Outperform
Jul 10, 2019Resumed
CCredit Suisse
Outperform
Apr 24, 2019Resumed
BB. Riley FBR
Buy$6.50+760.6%
Feb 15, 2019Initiated
CCredit Suisse
Outperform$7+826.8%
Oct 23, 2018Initiated
BB. Riley FBR
Buy$9+1,091.6%
Oct 13, 2017Reiterated
RY logoRRBC Capital Mkts
Outperform$6 → $5+562.0%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Angotti Vincent J.CHIEF EXECUTIVE OFFICERMar 13 '26Buy0.59213,310125,000800,705Mar 25 07:57 PM
Angotti Vincent J.CHIEF EXECUTIVE OFFICERFeb 12 '26Buy0.81105,36485,587586,954Feb 20 08:28 PM
Aslam ShakilChief Medical OfficerFeb 12 '26Buy0.8135,00028,43083,178Feb 20 08:27 PM
Dasu Badri NChief Engineering OfficerFeb 12 '26Buy0.8135,00028,43076,230Feb 20 08:25 PM
ASADORIAN RAFFIChief Financial OfficerFeb 12 '26Buy0.8145,00036,55491,256Feb 20 08:23 PM
Talphera, Inc. engages in the development and commercialization of therapies used in medically supervised settings. The firm's portfolio includes Nafamostat, LTX-608, and Niyad. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in San Mateo, CA.
CEO & DirectorMr. Vincent J. Angotti
Chief Financial OfficerMr. Raffi Mark Asadorian
Chief Medical OfficerDr. Shakil Aslam M.D.
Chief Engineering OfficerMr. Anil N. Dasu